Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.

Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ.

Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19.

PMID:
29459477
2.

T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth.

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G.

Oncoimmunology. 2017 Mar 17;6(4):e1302631. doi: 10.1080/2162402X.2017.1302631. eCollection 2017.

3.

CAR T Cell Therapy: A Game Changer in Cancer Treatment.

Almåsbak H, Aarvak T, Vemuri MC.

J Immunol Res. 2016;2016:5474602. doi: 10.1155/2016/5474602. Epub 2016 May 19. Review.

4.

Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA.

Gene Ther. 2015 May;22(5):391-403. doi: 10.1038/gt.2015.4. Epub 2015 Feb 5.

PMID:
25652098
5.

Transiently redirected T cells for adoptive transfer.

Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM.

Cytotherapy. 2011 May;13(5):629-40. doi: 10.3109/14653249.2010.542461. Epub 2010 Dec 21.

PMID:
21174490
6.

Non-MHC-dependent redirected T cells against tumor cells.

Almåsbak H, Lundby M, Rasmussen AM.

Methods Mol Biol. 2010;629:453-93. doi: 10.1007/978-1-60761-657-3_28.

PMID:
20387166
7.

A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2.

Paus E, Almåsbak H, Børmer OP, Warren DJ.

J Immunol Methods. 2003 Dec;283(1-2):125-39.

PMID:
14659905

Supplemental Content

Loading ...
Support Center